The human complement inhibitor Sushi Domain-Containing Protein 4 (SUSD4) expression in tumor cells and infiltrating T cells is associated with better prognosis of breast cancer patients

Holmquist E(2013)Sushi domain-containing protein 4 (SUSD4) inhibits complement by disrupting the formation of the classical C3 convertase FASEB J 27 2355-2366

Okroj M(2009)Is complement good or bad for cancer patients? A new perspective on an old dilemma Trends Immunol 30 286-292

Nodin B(2003)Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid Clin Exp Immunol 131 254-263

Jirstrom K(1999)Complement resistance of tumor cells: basal and induced mechanisms Mol Immunol 36 929-939

Blom AM(2008)Modulation of the antitumor immune response by complement Nat Immunol 9 1225-1235

Markiewski MM(2011)Chondroitin sulfate expression predicts poor outcome in breast cancer Int J Oncol 39 1421-1428

Lambris JD(2008)Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer J Clin Pathol 61 197-203

Donin N(2005)Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer J Clin Oncol 23 4695-4704

Jurianz K(2005)Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes Eur J Cancer 41 1628-1636

Ziporen L(2002)Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes Genome Biol 3 RESEARCH0034-14

Holmquist E(2013)Sushi domain-containing protein 4 (SUSD4) inhibits complement by disrupting the formation of the classical C3 convertase FASEB J 27 2355-2366

Okroj M(2009)Is complement good or bad for cancer patients? A new perspective on an old dilemma Trends Immunol 30 286-292

Nodin B(2003)Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid Clin Exp Immunol 131 254-263

Jirstrom K(1999)Complement resistance of tumor cells: basal and induced mechanisms Mol Immunol 36 929-939

Blom AM(2008)Modulation of the antitumor immune response by complement Nat Immunol 9 1225-1235

Markiewski MM(2011)Chondroitin sulfate expression predicts poor outcome in breast cancer Int J Oncol 39 1421-1428

Lambris JD(2008)Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer J Clin Pathol 61 197-203

Donin N(2005)Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer J Clin Oncol 23 4695-4704

Jurianz K(2005)Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes Eur J Cancer 41 1628-1636

Ziporen L(2002)Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes Genome Biol 3 RESEARCH0034-14